BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29783587)

  • 1. Re: Randomized Phase III Trial of Adjuvant Pazopanib versus Placebo after Nephrectomy in Patients with Localized or Locally Advanced Renal Cell Carcinoma.
    Laguna MP
    J Urol; 2018 Jun; 199(6):1393-1394. PubMed ID: 29783587
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial.
    Motzer RJ; Russo P; Haas N; Doehn C; Donskov F; Gross-Goupil M; Varlamov S; Kopyltsov E; Lee JL; Lim HY; Melichar B; Zemanova M; Rini B; Choueiri TK; Wood L; Reaume MN; Stenzl A; Chowdhury S; McDermott R; Michael A; Izquierdo M; Aimone P; Zhang H; Sternberg CN;
    Eur Urol; 2021 Mar; 79(3):334-338. PubMed ID: 33461782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
    Motzer RJ; Haas NB; Donskov F; Gross-Goupil M; Varlamov S; Kopyltsov E; Lee JL; Melichar B; Rini BI; Choueiri TK; Zemanova M; Wood LA; Reaume MN; Stenzl A; Chowdhury S; Lim HY; McDermott R; Michael A; Bao W; Carrasco-Alfonso MJ; Aimone P; Voi M; Doehn C; Russo P; Sternberg CN;
    J Clin Oncol; 2017 Dec; 35(35):3916-3923. PubMed ID: 28902533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Robert J. Motzer, Paul Russo, Naomi Haas, et al. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients with Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. Eur Urol 2021;79:334-8: PROTECTing Patients with Locally Advanced Kidney Cancer.
    Singla N; Pierorazio P; Allaf M; Ged Y
    Eur Urol; 2021 Jul; 80(1):e33-e34. PubMed ID: 33962807
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvant Pazopanib Does Not PROTECT Against Recurrence of High-Risk, Initially Localized Renal Cell Cancer but Does Provide Novel Insights.
    Stewart GD; Leibovich BC; Negrier S; Figlin RA
    J Clin Oncol; 2017 Dec; 35(35):3895-3897. PubMed ID: 29068785
    [No Abstract]   [Full Text] [Related]  

  • 6. A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma.
    Rini BI; Plimack ER; Takagi T; Elson P; Wood LS; Dreicer R; Gilligan T; Garcia J; Zhang Z; Kaouk J; Krishnamurthi V; Stephenson AJ; Fergany A; Klein EA; Uzzo RG; Chen DY; Campbell SC
    J Urol; 2015 Aug; 194(2):297-303. PubMed ID: 25813447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adjuvant AUO study of renal cell carcinoma after nephrectomy: randomized, double-blind, placebo-controlled phase III study (PROTECT - AN 30/10) to investigate the effectiveness and safety of pazopanib as adjuvant therapy in patients with localized or local advanced renal cell carcinoma after nephrectomy].
    Rexer H
    Urologe A; 2011 Apr; 50(4):489-92. PubMed ID: 21472622
    [No Abstract]   [Full Text] [Related]  

  • 8. Adjuvant therapy after nephrectomy for renal cell carcinoma.
    Ravaud A
    Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():33-36. PubMed ID: 30489037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib.
    Jacobs C; Kim DW; Straka C; Timmerman RD; Brugarolas J
    J Clin Oncol; 2013 Mar; 31(7):e114-7. PubMed ID: 23319695
    [No Abstract]   [Full Text] [Related]  

  • 10. Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma.
    Bonate PL; Suttle AB
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):231-40. PubMed ID: 23715625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pazopanib: in advanced renal cell carcinoma.
    Sanford M; Keating GM
    BioDrugs; 2010 Oct; 24(5):279-86. PubMed ID: 20649181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients.
    Poprach A; Fiala O; Chloupkova R; Melichar B; Lakomy R; Petrakova K; Zemanova M; Kopeckova K; Slaby O; Studentova H; Kopecký J; Kiss I; Finek J; Dusek L; Buchler T
    Anticancer Res; 2018 Jan; 38(1):449-456. PubMed ID: 29277808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pazopanib in renal cell carcinoma.
    Ward JE; Stadler WM
    Clin Cancer Res; 2010 Dec; 16(24):5923-7. PubMed ID: 21059813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma.
    Laguna MP
    J Urol; 2014 Jun; 191(6):1728-9. PubMed ID: 25280273
    [No Abstract]   [Full Text] [Related]  

  • 15. Surgical management of locally advanced and metastatic renal cancer: neoadjuvant and adjuvant strategies.
    Pignot G; Drai J; Patard JJ
    Minerva Urol Nefrol; 2014 Mar; 66(1):49-55. PubMed ID: 24721940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
    Koc G; Wang X; Luo Y
    Can J Urol; 2011 Dec; 18(6):5991-7. PubMed ID: 22166325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant and adjuvant treatment of renal cell carcinoma.
    Thillai K; Allan S; Powles T; Rudman S; Chowdhury S
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):765-76. PubMed ID: 22716493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective.
    Capri S; Porta C; Delea TE
    Clin Ther; 2017 Mar; 39(3):567-580.e2. PubMed ID: 28189363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial Comment to Systemic therapy in the management of localized and locally advanced renal cell carcinoma: Current state and future perspectives.
    Tatsugami K
    Int J Urol; 2019 May; 26(5):542-543. PubMed ID: 30943577
    [No Abstract]   [Full Text] [Related]  

  • 20. Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial.
    Doehn Ch; Richter A; Lehmacher W; Jocham D
    Folia Biol (Praha); 2003; 49(2):69-73. PubMed ID: 12779015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.